Early Time-Restricted Eating Cut Blood Sugar Fluctuations in Prediabetes
CHICAGO – Just 1 week of early time-restricted feeding (eTRF) cut fluctuations in blood sugar levels, and reduced the time that blood sugar was elevated, in people with prediabetes and a high BMI, according to the TRIO study. The difference in the mean amplitude of glycemic excursion (MAGE) — the standard for assessing short-term within-day […]
Breast Cancer Drugs May Weaken Effects of Weight-Loss Drugs
CHICAGO — Anti-obesity medications may not work quite as well in women taking certain breast cancer drugs, a researcher reported here. Among 99 breast cancer survivors, those taking aromatase inhibitors (AI) lost 42% less weight after a year of taking an anti-obesity medication than women not on AIs, said Sima Fansa, MD, of the Mayo […]
Are Athletes With T1D Putting Themselves at Risk for Recurrent Hypoglycemia?
CHICAGO – Nearly three-fourths of people with type 1 diabetes (T1D) who engaged in aerobic activity failed to follow guidelines for preventing hypoglycemia, according to a survey-based study. Guidelines state that if a person with T1D experiences severe hypoglycemia, they should not exercise for 24 hours, but 73% of those surveyed (n=102 adults) reported exercising […]
No Increase in Major Cardiac Events With Testosterone-Replacement Therapy
CHICAGO — Testosterone-replacement therapy was noninferior to placebo in the occurrence of major adverse cardiac events among men with hypogonadism and established or high risk for cardiovascular disease, the randomized TRAVERSE trial showed. At a mean follow-up of 33 months, the primary cardiovascular endpoint — first occurrence of any component of a composite of death […]
AMA to Amp Up Hospital Consolidation Scrutiny
CHICAGO — Physicians pressing for the American Medical Association (AMA) to do more on healthcare consolidation pushed through a resolution to produce in-depth annual reports on the topic that could be used to advocate for legislative change. At the association’s annual House of Delegates meeting this week, its Private Practice Physicians Section made the case […]
Airlines Need to Let Wheelchair Users Use Them on Planes, AMA Members Say
CHICAGO — Airlines need to do more to help patients in wheelchairs use them on the plane, members of the American Medical Association’s (AMA) House of Delegates said here Sunday, but they were divided on how to make that happen. Delegates attending a Sunday morning reference committee meeting were debating a resolution from two specialty […]
AMA Urged to Do More to Safeguard Adolescent Gender-Affirming Care
CHICAGO — How should the American Medical Association (AMA) respond to the rapidly increasing number of state prohibitions on gender-affirming care for adolescents? Delegates considered the topic during committee discussions at the AMA House of Delegates meeting Saturday. The AMA already has a policy in place for gender-affirming care, and a new draft resolution moves […]
FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO — Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived significantly longer if they received the selective FGFR inhibitor erdafitinib (Balversa) instead of chemotherapy, a randomized trial showed. Median overall survival (OS) increased from 7.8 months with physician’s choice of chemotherapy to 12.1 months with the targeted agent. Progression-free survival (PFS) […]
Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
CHICAGO — Upfront CDK4/6 inhibition or second-line use in advanced hormone receptor (HR)-positive/HER2-negative breast cancer led to similar cumulative progression-free survival (PFS) in a large randomized trial. Patients who received a CDK4/6 inhibitor plus an aromatase inhibitor (AI) as initial therapy and fulvestrant in the second line had a median PFS of 31.0 months at […]
New Data in NSCLC Bolster Support for Perioperative Immunotherapy
CHICAGO — A randomized trial testing the addition of perioperative pembrolizumab (Keytruda) to chemotherapy in operable non-small cell lung cancer (NSCLC) hit one of its two primary endpoints in an interim analysis, with a favorable trend for the other. All patients in the study received cisplatin-based neoadjuvant chemotherapy, and at 2 years, the event-free survival […]